Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Target Price at $57.75

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been given a consensus rating of “Moderate Buy” by the nine research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $56.7143.

A number of research firms recently weighed in on IMCR. Jefferies Financial Group lowered shares of Immunocore from a “buy” rating to a “hold” rating and lowered their price target for the stock from $48.00 to $33.00 in a research report on Monday, March 16th. Zacks Research upgraded shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Monday, April 20th.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently bought and sold shares of the company. Harbour Investments Inc. raised its stake in Immunocore by 60.2% during the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after purchasing an additional 388 shares during the period. DNB Asset Management AS raised its stake in Immunocore by 6.4% during the third quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock worth $295,000 after purchasing an additional 488 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Immunocore by 37.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after purchasing an additional 572 shares during the period. R Squared Ltd raised its stake in Immunocore by 7.4% during the fourth quarter. R Squared Ltd now owns 8,849 shares of the company’s stock worth $307,000 after purchasing an additional 606 shares during the period. Finally, Leonteq Securities AG purchased a new position in Immunocore during the fourth quarter worth about $30,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Stock Up 2.0%

NASDAQ IMCR opened at $29.41 on Wednesday. The company has a market cap of $1.49 billion, a P/E ratio of -53.47 and a beta of 0.74. Immunocore has a one year low of $27.56 and a one year high of $40.71. The business has a fifty day moving average price of $29.99 and a 200 day moving average price of $32.99. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The firm had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. Immunocore’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. Research analysts anticipate that Immunocore will post -0.16 EPS for the current fiscal year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.